
NEJM This Week — October 2, 2025
NEJM This Week
00:00
Olizarsin Lowers Triglycerides by Targeting APOC3
Summary of a phase 3 trial where olizarsin, an antisense oligonucleotide against APOC3, significantly reduced triglycerides versus placebo.
Transcript
Play full episode